Longitudinal study of the substantia nigra in Parkinson disease: A high-field (1) H-MR spectroscopy imaging study
The value of biomarkers in early diagnosis and development of therapeutics in Parkinson's disease (PD) is well established. We used proton magnetic resonance spectroscopy in a prospective, longitudinal study of 23 patients with early PD, naïve to dopaminergic therapy, and six age-matched health...
Gespeichert in:
| Veröffentlicht in: | Movement disorders 2015-09, Vol.30 (10), p.1400-1404 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1404 |
|---|---|
| container_issue | 10 |
| container_start_page | 1400 |
| container_title | Movement disorders |
| container_volume | 30 |
| creator | Seraji-Bozorgzad, Navid Bao, Fen George, Edwin Krstevska, Shana Gorden, Veronica Chorostecki, Jessica Santiago, Carla Zak, Imad Caon, Christina Khan, Omar |
| description | The value of biomarkers in early diagnosis and development of therapeutics in Parkinson's disease (PD) is well established.
We used proton magnetic resonance spectroscopy in a prospective, longitudinal study of 23 patients with early PD, naïve to dopaminergic therapy, and six age-matched healthy controls to examine the temporal changes in metabolic profile of substantia nigra over a period of 3 months.
N-acetyl aspartate to creatine ratio at month 3 was compared with baseline values in the PD and control groups, as well as the side-to-side difference of the ratio at baseline. By month 3, n-acetyl aspartate to creatine ratio had decreased by 4.4% in patients with PD (P = 0.024), without a concomitant change in healthy controls. The side-to-side asymmetry was significantly higher in the PD group (16.7%) vs. healthy controls (1.6%, P = 0.0024).
Estimation of change in the n-acetyl aspartate to creatine ratio appears to be a fast, quantifiable, and reliable marker of dopaminergic neuronal viability in PD. |
| doi_str_mv | 10.1002/mds.26323 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1709709129</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1709709129</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-72d26392fa1881b35a819579daad41e741d991680e1b0e2289462bd7aa6296d83</originalsourceid><addsrcrecordid>eNo1UMFKw0AUXASxtXrwB2SP9ZC6b9Nsst5KUStEFNFzeOlu0tVkk-Ylh_69kVYYmDkMw8wwdgNiAULI-9rQQqpQhmdsClEIQSKjeMIuib6FAIhAXbCJVFImWsCU7dPGl64fjPNYcRrFgTcF73eW05BTj753yL0rO-TO83fsfpynxnPjyCLZB77iO1fugsLZyvA53PFN8PrBqbXbvmto27QH7mosnS-P8VfsvMCK7PWJZ-zr6fFzvQnSt-eX9SoNWpCqD2JpxhlaFghJAnkYYQI6irVBNEuw8RKM1qASYSEX9m_OUsncxIhKamWScMbmx9y2a_aDpT6rHW1tVaG3zUAZxEKPAKlH6-3JOuS1NVnbjY27Q_Z_U_gLqdpmIg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1709709129</pqid></control><display><type>article</type><title>Longitudinal study of the substantia nigra in Parkinson disease: A high-field (1) H-MR spectroscopy imaging study</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Seraji-Bozorgzad, Navid ; Bao, Fen ; George, Edwin ; Krstevska, Shana ; Gorden, Veronica ; Chorostecki, Jessica ; Santiago, Carla ; Zak, Imad ; Caon, Christina ; Khan, Omar</creator><creatorcontrib>Seraji-Bozorgzad, Navid ; Bao, Fen ; George, Edwin ; Krstevska, Shana ; Gorden, Veronica ; Chorostecki, Jessica ; Santiago, Carla ; Zak, Imad ; Caon, Christina ; Khan, Omar</creatorcontrib><description>The value of biomarkers in early diagnosis and development of therapeutics in Parkinson's disease (PD) is well established.
We used proton magnetic resonance spectroscopy in a prospective, longitudinal study of 23 patients with early PD, naïve to dopaminergic therapy, and six age-matched healthy controls to examine the temporal changes in metabolic profile of substantia nigra over a period of 3 months.
N-acetyl aspartate to creatine ratio at month 3 was compared with baseline values in the PD and control groups, as well as the side-to-side difference of the ratio at baseline. By month 3, n-acetyl aspartate to creatine ratio had decreased by 4.4% in patients with PD (P = 0.024), without a concomitant change in healthy controls. The side-to-side asymmetry was significantly higher in the PD group (16.7%) vs. healthy controls (1.6%, P = 0.0024).
Estimation of change in the n-acetyl aspartate to creatine ratio appears to be a fast, quantifiable, and reliable marker of dopaminergic neuronal viability in PD.</description><identifier>EISSN: 1531-8257</identifier><identifier>DOI: 10.1002/mds.26323</identifier><identifier>PMID: 26228901</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Aspartic Acid - analogs & derivatives ; Aspartic Acid - metabolism ; Biomarkers - metabolism ; Creatine - metabolism ; Female ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Parkinson Disease - metabolism ; Proton Magnetic Resonance Spectroscopy - methods ; Substantia Nigra - metabolism</subject><ispartof>Movement disorders, 2015-09, Vol.30 (10), p.1400-1404</ispartof><rights>2015 International Parkinson and Movement Disorder Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26228901$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seraji-Bozorgzad, Navid</creatorcontrib><creatorcontrib>Bao, Fen</creatorcontrib><creatorcontrib>George, Edwin</creatorcontrib><creatorcontrib>Krstevska, Shana</creatorcontrib><creatorcontrib>Gorden, Veronica</creatorcontrib><creatorcontrib>Chorostecki, Jessica</creatorcontrib><creatorcontrib>Santiago, Carla</creatorcontrib><creatorcontrib>Zak, Imad</creatorcontrib><creatorcontrib>Caon, Christina</creatorcontrib><creatorcontrib>Khan, Omar</creatorcontrib><title>Longitudinal study of the substantia nigra in Parkinson disease: A high-field (1) H-MR spectroscopy imaging study</title><title>Movement disorders</title><addtitle>Mov Disord</addtitle><description>The value of biomarkers in early diagnosis and development of therapeutics in Parkinson's disease (PD) is well established.
We used proton magnetic resonance spectroscopy in a prospective, longitudinal study of 23 patients with early PD, naïve to dopaminergic therapy, and six age-matched healthy controls to examine the temporal changes in metabolic profile of substantia nigra over a period of 3 months.
N-acetyl aspartate to creatine ratio at month 3 was compared with baseline values in the PD and control groups, as well as the side-to-side difference of the ratio at baseline. By month 3, n-acetyl aspartate to creatine ratio had decreased by 4.4% in patients with PD (P = 0.024), without a concomitant change in healthy controls. The side-to-side asymmetry was significantly higher in the PD group (16.7%) vs. healthy controls (1.6%, P = 0.0024).
Estimation of change in the n-acetyl aspartate to creatine ratio appears to be a fast, quantifiable, and reliable marker of dopaminergic neuronal viability in PD.</description><subject>Aged</subject><subject>Aspartic Acid - analogs & derivatives</subject><subject>Aspartic Acid - metabolism</subject><subject>Biomarkers - metabolism</subject><subject>Creatine - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Parkinson Disease - metabolism</subject><subject>Proton Magnetic Resonance Spectroscopy - methods</subject><subject>Substantia Nigra - metabolism</subject><issn>1531-8257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1UMFKw0AUXASxtXrwB2SP9ZC6b9Nsst5KUStEFNFzeOlu0tVkk-Ylh_69kVYYmDkMw8wwdgNiAULI-9rQQqpQhmdsClEIQSKjeMIuib6FAIhAXbCJVFImWsCU7dPGl64fjPNYcRrFgTcF73eW05BTj753yL0rO-TO83fsfpynxnPjyCLZB77iO1fugsLZyvA53PFN8PrBqbXbvmto27QH7mosnS-P8VfsvMCK7PWJZ-zr6fFzvQnSt-eX9SoNWpCqD2JpxhlaFghJAnkYYQI6irVBNEuw8RKM1qASYSEX9m_OUsncxIhKamWScMbmx9y2a_aDpT6rHW1tVaG3zUAZxEKPAKlH6-3JOuS1NVnbjY27Q_Z_U_gLqdpmIg</recordid><startdate>201509</startdate><enddate>201509</enddate><creator>Seraji-Bozorgzad, Navid</creator><creator>Bao, Fen</creator><creator>George, Edwin</creator><creator>Krstevska, Shana</creator><creator>Gorden, Veronica</creator><creator>Chorostecki, Jessica</creator><creator>Santiago, Carla</creator><creator>Zak, Imad</creator><creator>Caon, Christina</creator><creator>Khan, Omar</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201509</creationdate><title>Longitudinal study of the substantia nigra in Parkinson disease: A high-field (1) H-MR spectroscopy imaging study</title><author>Seraji-Bozorgzad, Navid ; Bao, Fen ; George, Edwin ; Krstevska, Shana ; Gorden, Veronica ; Chorostecki, Jessica ; Santiago, Carla ; Zak, Imad ; Caon, Christina ; Khan, Omar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-72d26392fa1881b35a819579daad41e741d991680e1b0e2289462bd7aa6296d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Aspartic Acid - analogs & derivatives</topic><topic>Aspartic Acid - metabolism</topic><topic>Biomarkers - metabolism</topic><topic>Creatine - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Parkinson Disease - metabolism</topic><topic>Proton Magnetic Resonance Spectroscopy - methods</topic><topic>Substantia Nigra - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seraji-Bozorgzad, Navid</creatorcontrib><creatorcontrib>Bao, Fen</creatorcontrib><creatorcontrib>George, Edwin</creatorcontrib><creatorcontrib>Krstevska, Shana</creatorcontrib><creatorcontrib>Gorden, Veronica</creatorcontrib><creatorcontrib>Chorostecki, Jessica</creatorcontrib><creatorcontrib>Santiago, Carla</creatorcontrib><creatorcontrib>Zak, Imad</creatorcontrib><creatorcontrib>Caon, Christina</creatorcontrib><creatorcontrib>Khan, Omar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Movement disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seraji-Bozorgzad, Navid</au><au>Bao, Fen</au><au>George, Edwin</au><au>Krstevska, Shana</au><au>Gorden, Veronica</au><au>Chorostecki, Jessica</au><au>Santiago, Carla</au><au>Zak, Imad</au><au>Caon, Christina</au><au>Khan, Omar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Longitudinal study of the substantia nigra in Parkinson disease: A high-field (1) H-MR spectroscopy imaging study</atitle><jtitle>Movement disorders</jtitle><addtitle>Mov Disord</addtitle><date>2015-09</date><risdate>2015</risdate><volume>30</volume><issue>10</issue><spage>1400</spage><epage>1404</epage><pages>1400-1404</pages><eissn>1531-8257</eissn><abstract>The value of biomarkers in early diagnosis and development of therapeutics in Parkinson's disease (PD) is well established.
We used proton magnetic resonance spectroscopy in a prospective, longitudinal study of 23 patients with early PD, naïve to dopaminergic therapy, and six age-matched healthy controls to examine the temporal changes in metabolic profile of substantia nigra over a period of 3 months.
N-acetyl aspartate to creatine ratio at month 3 was compared with baseline values in the PD and control groups, as well as the side-to-side difference of the ratio at baseline. By month 3, n-acetyl aspartate to creatine ratio had decreased by 4.4% in patients with PD (P = 0.024), without a concomitant change in healthy controls. The side-to-side asymmetry was significantly higher in the PD group (16.7%) vs. healthy controls (1.6%, P = 0.0024).
Estimation of change in the n-acetyl aspartate to creatine ratio appears to be a fast, quantifiable, and reliable marker of dopaminergic neuronal viability in PD.</abstract><cop>United States</cop><pmid>26228901</pmid><doi>10.1002/mds.26323</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1531-8257 |
| ispartof | Movement disorders, 2015-09, Vol.30 (10), p.1400-1404 |
| issn | 1531-8257 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1709709129 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Aged Aspartic Acid - analogs & derivatives Aspartic Acid - metabolism Biomarkers - metabolism Creatine - metabolism Female Humans Longitudinal Studies Male Middle Aged Parkinson Disease - metabolism Proton Magnetic Resonance Spectroscopy - methods Substantia Nigra - metabolism |
| title | Longitudinal study of the substantia nigra in Parkinson disease: A high-field (1) H-MR spectroscopy imaging study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T15%3A52%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Longitudinal%20study%20of%20the%20substantia%20nigra%20in%20Parkinson%20disease:%20A%20high-field%20(1)%20H-MR%20spectroscopy%20imaging%20study&rft.jtitle=Movement%20disorders&rft.au=Seraji-Bozorgzad,%20Navid&rft.date=2015-09&rft.volume=30&rft.issue=10&rft.spage=1400&rft.epage=1404&rft.pages=1400-1404&rft.eissn=1531-8257&rft_id=info:doi/10.1002/mds.26323&rft_dat=%3Cproquest_pubme%3E1709709129%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1709709129&rft_id=info:pmid/26228901&rfr_iscdi=true |